Objective: To determine the safety and efficacy of fluvoxamine for the treatment of children and adolescents with obsessive-compulsive disorder (OCD) with a double-blind, placebo-controlled, multicenter study.
Obsessive-compulsive disorder (OCD) is a neuropsychiatric condition that commonly presents during childhood or adolescence (Adams, 1973; Pauls et al., 1995; Rapoport, 1989; Riddle et al., 1990; Swedo et al., 1989) . For adults with OCD, a wealth of clinical studies support the efficacy of treatment with medications, specifically, the serotonin reuptake inhibitor clomipramine (DeVeaugh-Geiss et al., 1992) and the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine (Goodman et al., 1989) , fluoxetine (Tollefson et al., 1994) , sertraline (Greist et al., 1995) , and paroxetine (Dunbar et al., 1995) , as well as cognitive-behavioral psychotherapies.
Over the past decade, emerging clinical literature supports the efficacy of various treatments for children and adolescents with OCD. In single-center studies, clomipramine was compared to placebo (Flament et al., 1985) and to desipramine (Leonard et al., 1989) and was found to be efficacious. A double-blind substitution of desipramine in children receiving long-term clomipramine treatment demonstrated a high relapse rate when children stopped taking clomipramine (Leonard et al., 1991) . In an 8-week, multicenrer, placebo-controlled, parallel-group study of 60 children and adolescents, clomipramine was effective (DeVeaugh-Geiss et al., 1992) . In double-blind comparisons with placebo in children and adolescents with OCD, fluoxetine and sertraline were generally well tolerated and significantly better than placebo on major outcome variables (March et al., 1998; Riddle et al., 1992) . Recent uncontrolled studies of cognitive-behavioral therapies for children and adolescents with OCD also have been encouraging (Ma rch, 1995; March et al., 1997) .
Fluvoxamine, a monocyclic SSRI, has been extensively studied for the treatment of OCD in adults. However, few data regarding the use of fluvoxamine in children and adolescents exist. The results of an open-label study of fluvoxamine in 14 adolescent inpatients with OCD or depression were encouraging (Apter et al., 1994) . The efficacy of fluvoxamine in youngsters with OCD has not been evaluated in a controlled study. We conducted a 10-week, multicenter, randomized, double-blind, placebo-controlled trial with fluvoxamine. The hypothesis was that fluvoxamine was more effective than placebo for the treatment of children and adolescents with OCD.
METHOD Study Design
Children and adolescents were recruited at 17 investigative sires throughout the United States from July 1991 through August 1994. The study, approved by the institutional review board at each site, consisted of three periods: screening, titration, and maintenance. The 7-to 14-day screening period was used to evaluate subjects for suitability, to provide a washout of prior psychotropic medications, and to screen out rapid placebo responders. During this period, subjects who met entry criteria were given single-blind placebo and were evaluated for eligibility by physical examination, laboratory tests, electrocardiogram (EGG), symptom rating scales, and vital signs. At the conclusion of the screening period, baseline evaluations (i.e., symptom severity ratings) were obtained and eligible subjects were randomly assigned to the 10-week, double-blind study drug (baseline; day 1). 
